Table 4.
Overview of commercially produced capsules using ECDDT.
| Product Name | Manufacturer/Country of Origin | Composition of Capsule | Pharmacopoeial Acid Resistance |
|---|---|---|---|
| A. Capsules prepared from pH-dependent polymers | |||
| AR Caps® | CapsCanada/Canada | HPMC, HMPCP | No [29] |
| EnTRinsicTM | Capsugel®/USA | CAP | Ph. Eur., USP, JP [60] |
| VCaps® Enteric | Capsugel®/USA | HPMC, HPMCAS | Ph. Eur., USP, JP [66] |
| B. Capsules prepared from gel-forming polymers | |||
| DRcapsTM | Capsugel®/France | HPMC, gellan gum | No [29] |
| EMBO CAPS® AP | Suhueng Capsule/ Republic of Korea |
HPMC, pectin | No [75] |
| BioVXR® | BioCaps®/USA | HPMC, gellan gum/pectin 1 |
No [75] |
| AGCcapsTM HD | ACG/India | HPMC 2 | Not specified |
1 Derived composition based on an associated patent [84]; 2 other components are not listed.